吡喃阿霉素与奥沙利铂治疗原发性肝癌比较分析.docVIP

吡喃阿霉素与奥沙利铂治疗原发性肝癌比较分析 　　[摘要] 目的 比较奥沙利铂和吡喃阿霉素对原发性肝癌的临床治疗效果，为原发性肝癌选择临床化疗方案提供依据，以达到治疗方案合理、有效、安全、经济的目的。 方法 整群选取2013年9月―2015年3月到该院住院治疗的原发性肝癌患者158例，将患者随机分为两组，每组79例；治疗时，观察组患者给予奥沙利铂，对照组给予吡喃阿霉素，比较两组患者治疗有效率、不良反应发生率、病程进展时间、临床症状改善率等。结果 观察组的患者治疗有效率为79.75%，对照组为60.76%，结果表明观察组的治疗效果明显高于对照组，对照组病情无进展时间为（6±2.4）个月，观察组病情无进展时间为（9±3.1）个月，观察组疾病无进展时间比对照组长；另外，观察组患者不良反应发生率和临床症状改善率与对照组相比无明显优势。 结论 从不良反应发生率和临床症状改善率来看，吡喃阿霉素和奥沙利铂治疗原发性肝癌无差异，但奥沙利铂对原发性肝癌的治疗效果和病情控制效果比吡喃阿霉素好，值得临床推广。 　　[关键词] 吡喃阿霉素；奥沙利铂；原发性肝癌 　　[中图分类号] R735 [文献标识码] A [文章编号] 1674-0742（2015）11（b）-00119-02 　　[Abstract] Objective To compare the clinical effect of pirarubicin and oxaliplatin in treatment of patients with primary liver cancer so as to provide basis for selecting clinical chemotherapy regimens to make the treatment more rational， effective， safe and economical. Methods 158 patients with primary liver cancer admitted to our hospital from September 2013 to March 2015 were selected and randomly divided into the study group and the control group， with 79 cases in each group. The study group was treated with oxaliplatin， while the control group was treated with pirarubicin. The response rate， incidence of adverse reaction， disease-progression-free duration， improvement rate of clinical symptoms was observed and compared between two groups. Results The response rate was 79.75% in the study group and 60.76% in the control group， and the results showed that the response rate of study group was significantly higher than that of the control group. The disease-progression-free duration [（6±2.4） m vs （9±3.1） m] was shorter in the control group than in the observation group. No statistically significant difference can be found in the improvement rate of clinical symptoms and incidence of adverse reaction between the study group and the control group. Conclusion In terms of incidence of adverse reaction and improvement rate of clinical symptoms， there was no statistically significant difference between pirarubicin and oxaliplatin in trea